The Thr92Ala 5′ Type 2 Deiodinase Gene Polymorphism Is Associated with a Delayed Triiodothyronine Secretion in Response to the Thyrotropin-Releasing Hormone–Stimulation Test: A Pharmacogenomic Study
- 1 December 2010
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 20 (12) , 1407-1412
Abstract
Background: The common Thr92Ala D2 polymorphism has been associated with changes in pituitary–thyroid axis homeostasis, but published results are conflicting. To investigate the effects of the Thr92Ala polymorphism on intrathyroidal thyroxine (T4) to triiodothyronine (T3) conversion, we designed prospective pharmacogenomic intervention aimed to detect differences in T3 levels after thyrotropin (TSH)-releasing hormone (TRH)–mediated TSH stimulation of the thyroid gland. Methods: Eighty-three healthy volunteers were screened and genotyped for the Thr92Ala polymorphism. Fifteen volunteers of each genotype (Thr/Thr, Thr/Ala, and Ala/Ala) underwent a 500 mcg intravenous TRH stimulation test with serial measurements of serum total T3 (TT3), free T4, and TSH over 180 minutes. Results: No differences in baseline thyroid hormone levels were seen among the study groups. Compared to the Thr/Thr group, the Ala/Ala group showed a significantly lower TRH-stimulated increase in serum TT3 at 60 minutes (12.07 ± 2.67 vs. 21.07 ± 2.86 ng/dL, p = 0.029). Thr/Ala subjects showed an intermediate response. Compared to Thr/Thr subjects, the Ala/Ala group showed a blunted rate of rise in serum TT3 as measured by mean time to 50% maximum delta serum TT3 (88.42 ± 6.84 vs. 69.56 ± 6.06 minutes, p = 0.028). Subjects attained similar maximal (180 minutes) TRH-stimulated TT3 levels. TRH-stimulated TSH and free T4 levels were not significantly different among the three genotype groups. Conclusions: The commonly occurring Thr92Ala D2 variant is associated with a decreased rate of acute TSH-stimulated T3 release from the thyroid consistent with a decrease in intrathyroidal deiodination. These data provide a proof of concept that the Thr92Ala polymorphism is associated with subtle changes in thyroid hormone homeostasis.Keywords
This publication has 25 references indexed in Scilit:
- Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditisClinical Endocrinology, 2009
- The Role of Type 1 and Type 2 5′-Deiodinase in the Pathophysiology of the 3,5,3′-Triiodothyronine Toxicosis of McCune-Albright SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2008
- Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritisHuman Molecular Genetics, 2008
- Ala92 Type 2 Deiodinase Allele Increases Risk for the Development of HypertensionHypertension, 2007
- The Thr92Ala Deiodinase Type 2 ( DIO2 ) Variant Is Not Associated with Type 2 Diabetes or Indices of Insulin Resistance in the Old Order of AmishThyroid®, 2005
- Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humansJournal of Clinical Investigation, 2005
- A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parametersAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Thyroid hormone receptors and type I iodothyronine 5′-deiodinase activity of human thyroid toxic adenomas and benign cold nodulesExperimental and Clinical Endocrinology & Diabetes, 2002
- The Clinical Impact of the Thyrotropin-Releasing Hormone TestThyroid®, 1998
- Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroidMolecular and Cellular Endocrinology, 1987